CERO THERAPEUTICS HOLDINGS INC
For the period ended Dec 31, 2023. Filed Apr 2, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 2, 2024
CERO$0.00-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $96,873 | $475,870 |
| Prepaid expenses and other assets | 27,426 | 225,188 |
| Money market funds held in Trust Account | 8,436,311 | — |
| Restricted cash held in Trust Account | — | 41,665,974 |
| TOTAL ASSETS | $8,560,610 | $42,367,032 |
| LIABILITIES, REDEEMABLE COMMON STOCK, AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $3,535,084 | $1,653,120 |
| Income tax payable | 23,633 | 599,159 |
| Shareholder redemption liability | — | 27,842,747 |
| Working capital loan – related party | 1,555,000 | 650,000 |
| Excise tax payable | 56,389 | — |
| Due to Affiliate | 3,315 | 3,315 |
| Total current liabilities | 5,173,421 | 30,748,341 |
| LONG TERM LIABILITIES | ||
| Deferred underwriting fee payable | 9,150,000 | 9,150,000 |
| Total liabilities | 14,323,421 | 39,898,341 |
| COMMITMENTS AND CONTINGENCIES | ||
| REDEEMABLE COMMON STOCK | ||
| Class A Common stock subject to possible redemption, $0.0001 par value, 764,957 and 1,288,298 shares at redemption value of $11.03 and $10.26 per share as of December 31, 2023 and 2022, respectively | 8,436,311 | 13,468,845 |
| STOCKHOLDERS’ DEFICIT | ||
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding | — | — |
| Class A common stock; $0.0001 par value; 60,000,000 shares authorized; 5,481,250 and 885,000 shares issued and outstanding (excluding 764,957 and 1,288,298 shares subject to possible redemption) as of December 31, 2023 and 2022, respectively | 547 | 88 |
| Class B common stock; $0.0001 par value; 10,000,000 shares authorized; 0 and 4,596,250 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | 459 |
| Additional paid-in capital | — | — |
| Accumulated deficit | (14,199,669) | (11,000,701) |
| Total stockholders’ deficit | (14,199,122) | (11,000,154) |
| TOTAL LIABILITIES, REDEEMABLE COMMON STOCK, AND STOCKHOLDERS’ DEFICIT | $8,560,610 | $42,367,032 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.